Although Alzheimer’s Disease (AD) is mainly considered a neuronal disease, much evidence points to a vascular pathogenetic involvement in its etiology. We recently demonstrated that an impairment of endothelial function may occur in AD patients, associated with an increase of Tissue Factor Pathway Inhibitor (TFPI), the serine protease inhibitor induced by endothelial injury, and higher Homocysteine or lower Folate plasma levels. To investigate central and plasmatic source of TFPI, we now evaluated the Cerebrospinal Fluid (CSF) levels in a cohort of subjects affected by AD, other neurodegenerative diseases and healthy controls, where the presence of major vascular disorders was ruled out with a thorough clinical, laboratory and neuroimaging assessment, and acute or chronic cerebrovascular disease patients. Moreover, to figure out if the increased TFPI levels are related to neurodegeneration, Tau and p-Tau proteins levels were also evaluated. Our study demonstrates for the first time an abnormally high CSF levels of TFPI in AD, also related to neurodegeneration, strengthening the hypothesis that an impairment of endothelial function may occurs despite the absence of manifest cerebrovascular lesions. Therefore, TFPI may represent a candidate marker of endothelial damage in AD and it might be used to monitor therapeutic interventions on vascular risk factors.

Piazza, F., Galimberti, D., Borroni, B., Padovani, A., Scarpini, E., Ferrarese, C. (2011). Increased levels of tissue factor pathway inhibitor in cerebrospinal fluid are related to neurodegeneration in alzheimer’s disease patients. JOURNAL OF ALZHEIMER'S DISEASE, 23(supplement 1), 69-70 [10.3233/JAD-2010-1433].

Increased levels of tissue factor pathway inhibitor in cerebrospinal fluid are related to neurodegeneration in alzheimer’s disease patients

PIAZZA, FABRIZIO
Primo
;
FERRARESE, CARLO
2011

Abstract

Although Alzheimer’s Disease (AD) is mainly considered a neuronal disease, much evidence points to a vascular pathogenetic involvement in its etiology. We recently demonstrated that an impairment of endothelial function may occur in AD patients, associated with an increase of Tissue Factor Pathway Inhibitor (TFPI), the serine protease inhibitor induced by endothelial injury, and higher Homocysteine or lower Folate plasma levels. To investigate central and plasmatic source of TFPI, we now evaluated the Cerebrospinal Fluid (CSF) levels in a cohort of subjects affected by AD, other neurodegenerative diseases and healthy controls, where the presence of major vascular disorders was ruled out with a thorough clinical, laboratory and neuroimaging assessment, and acute or chronic cerebrovascular disease patients. Moreover, to figure out if the increased TFPI levels are related to neurodegeneration, Tau and p-Tau proteins levels were also evaluated. Our study demonstrates for the first time an abnormally high CSF levels of TFPI in AD, also related to neurodegeneration, strengthening the hypothesis that an impairment of endothelial function may occurs despite the absence of manifest cerebrovascular lesions. Therefore, TFPI may represent a candidate marker of endothelial damage in AD and it might be used to monitor therapeutic interventions on vascular risk factors.
Abstract in rivista
Alzheimer’s Disease, Tissue Factor Pathway Inhibitor
English
2011
23
supplement 1
69
70
none
Piazza, F., Galimberti, D., Borroni, B., Padovani, A., Scarpini, E., Ferrarese, C. (2011). Increased levels of tissue factor pathway inhibitor in cerebrospinal fluid are related to neurodegeneration in alzheimer’s disease patients. JOURNAL OF ALZHEIMER'S DISEASE, 23(supplement 1), 69-70 [10.3233/JAD-2010-1433].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/137166
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
Social impact